AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 7 , ISSUE 2 ( July-December, 2023 ) > List of Articles


The Safety of Covishield (ChAdOx1 nCoV-19) Vaccine after Three Doses Vaccination under Mass Vaccination Program of Government of India

Rahat Kumar, Jaswinder Singh, Narinder Singh, Vikram Bhandari

Keywords : Coronavirus disease-2019, Covishield, ChAdOx1 nCoV-19, Solicited, Unsolicited

Citation Information : Kumar R, Singh J, Singh N, Bhandari V. The Safety of Covishield (ChAdOx1 nCoV-19) Vaccine after Three Doses Vaccination under Mass Vaccination Program of Government of India. Curr Trends Diagn Treat 2023; 7 (2):36-42.

DOI: 10.5005/jp-journals-10055-0166

License: CC BY-NC 4.0

Published Online: 26-03-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Aims and objectives: In coronavirus disease-2019 (COVID-19) disease, there is no antiviral drugs, hence, Covishield vaccination is the best way of prevention. In India, after two doses of vaccination drive, there has been reports of adverse drug events (ADEs) but there has been creation of misinformation about the safety of the vaccine in some reports. Only few studies are available to monitor the ADEs after the third dose of COVID-19 vaccine. Therefore, this study was planned to establish the safety of Covishield vaccine after three doses. Materials and methods: An observational, non-interventional, retrospective study based on surveillance was conducted to assess the safety of Covishield vaccine after three doses. The vaccine was given by Department of Immunization, Preventive and Social Medicine Department, Sri Guru Ram Das Hospital, Amritsar. Subjects were instructed to record solicited/unsolicited adverse reactions in the proforma provided to them in English/Hindi/Punjabi language and were instructed to record ADEs up to 42 days post-vaccination period. Results: A total of 1,364, 1,340, and 1,296 subjects were given the first, second, and third doses of vaccine. The most common solicited ADEs after the third dose with duration was pain at injection site in 48.1% of subjects for 1 day, mild fever temperature ≤100.5°F for 2 days, malaise in 13.1%, injection site swelling in 7%, headache in 5%, myalgia in 4%, chills in 2.5%, rigors in 1.4% of the subjects for 1 day. Adverse drug events seen in subjects with comorbidities were 62.2% after the first dose, 26.2% after the second dose, and 11.4% after the third dose showing a significant reduction in ADEs after each dose. Conclusion: Covishield vaccine is safe and effective after the third dose as compared with the second and first dose.

PDF Share
  1. WHO Director-General's opening remarks at the media briefing on COVID-19, 11 March 2020. Source:–11-03-2020. Retrieved on 20.10.2022.
  2. Stephen S, Issac A, Radhakrishnan RV, et al. Scrutiny of COVID-19 response strategies among severely affected European nations. Osong Public Health Res Perspect 2021;12:203–214. DOI: 10.24171/j.phrp.2021.0068.
  3. WHO. Draft landscape of COVID-19 candidate vaccines. 2020. Source: COVID-19-candidat vaccines. Retrieved on 20.10.2022.
  4. Akst J. COVID-19 vaccine frontrunners. The Scientist. 2020. 67382. Accessed on 20.10.2022.
  5. Ray M (6 May 2020). 30 Covid-19 vaccines in different stages of development: Scientists to PM Modi” ( Retrieved on 20.10.2022.
  6. Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca ( BBC News. 3 January 2021. Retrieved on 20.10.2022.
  7. Expert panel recommends Bharat Biotech's Covaxin for restricted emergency use. News18. 2 January 2021. Retrieved on 20.10.2022.
  8. Coronavirus disease (COVID-19): Vaccines serum – protection from birth onwards. ChAdOx1 nCoV-19 corona virus vaccine (Recombinant) COVISHIELD™. Available at: Accessed on 20.10.2022.
  9. World's largest vaccination programme begins in India on January 16. https://ww begins-in-india-on-01-16/article33582069.ece. The Hindu. 15 January 2021. Retrieved 16 January 2021. Retrieved on 20.10.2022.
  10. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021;21:637–646. DOI: 10.1016/S1473-3099(20)30942-7.
  11. Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111. DOI: 10.1016/S0140-6736(20)32661-1.
  12. Experts clear Russia's Sputnik Covid-19 vaccine for use in India ( Hindustan Times. 12 April 2021. Retrieved on 20.10.2022.
  13. Vaccination Statistics. Retrieved on 20.10.2022.
  14. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021;385(25):2348–2360. DOI: 10.1056/NEJMoa2105290.
  15. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021;70:46–51. DOI: 10.15585/mmwr.mm7002e1
  16. Carli G, Nichele I, Ruggeri M, et al. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med 2021;16(3):803–804. DOI: 10.1007/s11739-021-02685-0.
  17. Fact sheet for vaccine recipient approved for restricted use in emergency situation of in prevention of (COVID-19) disease in individuals 18 years of age and older. Retrieved on 20.10.2022.
  18. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999;20(2):109–117. DOI: 10.2165/00002018-199920020-00002.
  19. The Clinical Establishment (registration and regulation) act, 2010. Source: Retrieved on 20.10.2022.
  20. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 2021;385(24):e85. DOI: 10.1056/NEJMoa2114228.
  21. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021;385(24):e83. DOI: 10.1056/NEJMoa2114114.
  22. Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol 2022;23(6):940–946. DOI: 10.1038/s41590-022-01212-3.
  23. Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults – United States, August-December 2021. MMWR Morb Mortal Wkly Rep 2022;71(4):118–124. DOI: 10.15585/mmwr.mm7104a2.
  24. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384(15):1412–1423. DOI: 10.1056/NEJMoa2101765
  25. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Share RSS. COVID-19 Vaccine (ChAdOx1-S [recombinant]). Source: Retrieved on 20.10.2022.
  26. Common Side Effects (AEFI). Min. Health & Family Welfare, GoI. Retrieved on 20.10.20.
  27. Information for UK recipients. Medicines and Healthcare Products Regulatory Agency, UK. Retrieved on 20.10.20.
  28. Parida SP, Sahu DP, Singh AK, et al. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol 2022;94(6):2453–2459. DOI: 10.1002/jmv.27655
  29. Pawar PN, Chavhan SS, Jadhao VF, et al. To study adverse effect following immunization (AEFI) and COVID-19 infection amongst COVID-19 vaccine beneficiaries. J Assoc Physicians India 2022;70(2):11–12. PMID: 35436817.
  30. Kaur U, Ojha B, Pathak BK, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinMed 2021;38:101038. DOI: 10.1016/j.eclinm.2021.101038.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.